|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM368319857 |
| 003 |
DE-627 |
| 005 |
20240411232324.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240212s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.109930
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1372.xml
|
| 035 |
|
|
|a (DE-627)NLM368319857
|
| 035 |
|
|
|a (NLM)38342415
|
| 035 |
|
|
|a (PII)S1521-6616(24)00041-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Baydemir, Ilayda
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Trained immunity-inducing vaccines
|b Harnessing innate memory for vaccine design and delivery
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.03.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a While the efficacy of many current vaccines is well-established, various factors can diminish their effectiveness, particularly in vulnerable groups. Amidst emerging pandemic threats, enhancing vaccine responses is critical. Our review synthesizes insights from immunology and epidemiology, focusing on the concept of trained immunity (TRIM) and the non-specific effects (NSEs) of vaccines that confer heterologous protection. We elucidate the mechanisms driving TRIM, emphasizing its regulation through metabolic and epigenetic reprogramming in innate immune cells. Notably, we explore the extended protective scope of vaccines like BCG and COVID-19 vaccines against unrelated infections, underscoring their role in reducing neonatal mortality and combating diseases like malaria and yellow fever. We also highlight novel strategies to boost vaccine efficacy, incorporating TRIM inducers into vaccine formulations to enhance both specific and non-specific immune responses. This approach promises significant advancements in vaccine development, aiming to improve global public health outcomes, especially for the elderly and immunocompromised populations
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a BCG
|
| 650 |
|
4 |
|a Innate immunity
|
| 650 |
|
4 |
|a Non-specific effects
|
| 650 |
|
4 |
|a Trained immunity
|
| 650 |
|
4 |
|a Vaccines
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a BCG Vaccine
|2 NLM
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 700 |
1 |
|
|a Dulfer, Elisabeth A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Netea, Mihai G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Domínguez-Andrés, Jorge
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 261(2024) vom: 26. Apr., Seite 109930
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:261
|g year:2024
|g day:26
|g month:04
|g pages:109930
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.109930
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 261
|j 2024
|b 26
|c 04
|h 109930
|